Whitehawk Therapeutics adds Vijay Iyengar to board of directors
The clinical-stage oncology company named the former Incyte executive as a Class III director effective September 9, 2026.
SEC filing
Latest
2 stories
Thursday, September 10
Thursday, August 6
Whitehawk reports Q2 2026 results, HWK-206 trial on track for Q3 start
Two Phase 1 studies continue enrolling and cash of $190.0 million is expected to fund operations into 2H 2028, the company said.
SEC filing